135328-57-3

Upstream product

• 99-42-3 methyl (4-hydroxy-3-nitro)benzoate 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 

Downstream Products

• 1373491-25-8 3-[2-(4-adamantan-1-ylphenoxy)acetylamino]-4-hydroxybenzoic acid isopropyl ester 
• 1216156-34-1 isopropyl 3-amino-4-hydroxybenzoate 
• 17903-89-8 3-nitro-4-phenylmethoxybenzoic acid 
• 135328-63-1 7-benzyloxy-4-methoxycarbonylindole 

Relevant academic research and scientific papers

N-(3-nitro-4-alkoxybenzoyl)amino acid compounds as well as preparation method and application thereof

The invention discloses N-(3-nitro-4-alkoxybenzoyl)amino acid compounds as well as a preparation method and an application thereof and belongs to the field of medicines. 4-hydroxy-3-nitrobenzoic acidis subjected to methanol esterification, bromo-alkane substitution, hydrolysis and chlorination and then acylated with L-phenylglycine, R2 which is L-phenylglycine sodium salt is obtained, and the N-(3-nitro-4-alkoxybenzoyl)amino acid compounds are obtained after hydrolysis. The N-(3-nitro-4-alkoxybenzoyl)amino acid compounds have novel chemical structures, have good effects in an in-vitro xanthine oxidase inhibition activity test and can be used for treating and preventing gout diseases.

ARYLOXYPHENOXYACETYL-BASED COMPOUND HAVING HIF-1 INHIBITION ACTIVITY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT

Disclosed are a compound inhibitory of HIF-1 activity, a method for preparing the same, and a pharmaceutical composition comprising the same as an active ingredient. The compound has anticancer activity which is attributable to its inhibitory activity against HIF-1, but not to non-selective cellular toxicity. Thus, having inhibitory activity against HIF-1, the compound or a pharmaceutically acceptable salt thereof can be used as an ingredient in an anticancer agent for various cancers including large intestine cancer, hepatic cancer, stomach cancer and breast cancer. Further, the compound or a pharmaceutically acceptable salt thereof is applicable to the treatment of diabetic retinopathy or arthritis which is aggravated upon the activation of VEGFA by HIF-1.

Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors

The invention is concerned with novel heterobicyclic derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, V, W, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used as medicaments.